03_03_06

Express Mail Label No.: EV 695510665 US

Date of Deposit: March 1, 2006

Attorney Docket No.: 25619-50

Keg, No. 48, 128

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ACANTS:

Schoenfeld et al.

AL NUMBER:

09/806,400

EXAMINER: R. Schwadron

FILING DATE:

March 30, 2001

ART UNIT:

1644

For:

COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF

ATHEROSCLEROSIS

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page), in duplicate;
- 3. Copies of Cited References: A3-5; B4-5; C34-40; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 25619-501 RCE. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Wor R. Elrifi, Reg. No. 39,529

Matthew Pavao, Reg. No. 50,572

Attorney/Agent for Applicants

c/o MINTZ LEVIN

Tel.: (617) 542-6000

Fax: (617) 542-2241

Customer No.; 30623

TRA 2127036v.1

Dated: March 1, 2006

Express Mail Label No.: EV 695510665 US

Date of Deposit: March 1, 2006

Attorney Docket No. 25619-501 RCE

THE UNITED STATES PATENT AND TRADEMARK OFFICE

TEICHIVIS.

Schoenfeld et al.

ERMONDENE MBER:

09/806,400

EXAMINER:

R. Schwadron

FILING DATE:

March 30, 2001

ART UNIT:

1644

For:

COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF

ATHEROSCLEROSIS

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicant:

Shoenfeld et al.

U.S.S.N.:

09/806,400

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25619-501 RCE.

Respectfully submitted,

for.

Lvór R. Elrifi, Reg. No. 39,529 Matthew Pavao, Reg. No. 50,572 Attorney/Agent for Applicants


Reg. No. 48, 128

c/o MINTZ LEVIN Tel.: (617) 542-6000 Fax: (617) 542-2241

Customer No.; 30623

Dated: March 1, 2006

TRA 2127032v.1



Page 1 of 1 Attorney Docket No.: 25619-501 RCE

Please type a plus sign (+) in this box

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)							Application Number Filing Date		09/806,400 March 30, 2001 Shoenfeld			
							Group Art Unit					
							Examiner Name R. Schwadron					
							Attorney Docket N	lumber	25619-501			
									5.0		J	
Exam Initials	Cite No.	U.S. Patent Document No.		issı	ssue Date N		Name of Patentee(s) or Applicant(s)		Class	Sub Filing Date If Appropria		Date ropriate
	- 1		230			IDL IO	ICD ADDITION DO	OLIMENTO.		2- N		
Exam Initials	Cite No.	U.S. Publishe Application No		d Published		Name of Patentee(s) or Applicant(s)			Class	Sub Class	Filing Date	
	A3	2004	4/0047870 A	A1 03/11/04		Harats et al.			424	184.1	722	лорпас
	A4	2005/0148499 A		\1	1 07/07/05		Harats et al.		514	8		
	A5	2005/0197283 A		A1	09/08/05		Harats et al.		514	8		
		- (4)			F	OREIC	ON PATENT DOCUME	NTS	1946		. <u> </u>	
Exam Initials	Cite No.	Foreig Office	n Patent Do Number	ocum	ment Name o		of Patentee(s) or Appli	cant(s)	Date of Transla Publication Yes		slation No	
	В4	WO 01/68119 A1		A1	KAR		AROLINSKA INNOVATIONS AB		09/20/01			
,	B5	WO 01/68124 a2				THE BRIGHAM AN HOSPITAL, INC.		N'S	09/20/01			
	139		01	THEF	R PRIOR AF	RT – NO	ON PATENT LITERATU	JRE DOCUMEN	ITS	lovi See		
Exam Initials	Cite No.	Name	of Author,	Title	(when appro	priate)	, Publication, Volume,	Page(s), Date, E	itc.			
	C34	Ameli et al. Arteroscler. Thromb. Vasc. Biol., 16(8):1074-1079 (1996)										
	C35	Kobayashi et al. <i>J. Lipid Res.</i> , 42:697-709 (2001)										
	C36	Lindquist, S. Ann. Rev. Biochem., 55:1151-1191 (1986)										
	C37	Maron et al. Immunol. Lett., Abstract 581, 73(2-3):217 (2000)										
	C38	Schlesinger, M. J. Cell Biol., 103:321-325 (1986)										
	C39	Xiao et al. Clin. Immunol. Immunopathol., 85(2):119-128 (1997)										
	C40	Xu et al. Arteroscler. Thromb., 12:789-799 (1992)										
Serial No)		, filed _				viously cited by or su , and relied u d divisional application	pon for an ear			lication,	,
Examiner Signature						,,		Date	-			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.